U.S. pharma giant copyright scrapped two experimental weight loss tablets previous year—a at the time-everyday capsule, lotiglipron, because of elevated liver enzymes as well as a two times-every day tablet, danuglipron, as a result of robust Unwanted side effects—but CEO Albert Bour